|Email Newsletters from Pharmaceutical Technology and Pharmaceutical Technology Europe|
News from Europe's pharmaceutical manufacturing industry coupled with upcoming events, and exclusive articles and interviews from industry experts.
Addressing Rouge in Biopharmaceutical Manufacturing Systems
Stainless steel is the primary construction material for pharmaceutical and biopharmaceutical processing equipment. Prized for its ability to resist corrosion, stainless steel comes in hundreds of types and subtypes. Austenitic stainless steel is the most common type in these applications. It is nonhardened, nonmagnetic, and easily welded, and it resists heat and chemical sterilization and corrosion. The most common austenitic stainless steels are 304, 304L, 316, and 316L. “L” refers to low carbon content (i.e., 0.03% instead of 0.08%). The base metal of 304 and 316 stainless steels is iron (62–65%), which is combined with chromium (16–20%), nickel (8–14%), and other components such as carbon, silicon, and molybdenum (1).
Stainless steel becomes corrosion-resistant during a process called self-passivation, when the metal surface, which must be clean, comes into contact with oxygen to form a nonreactive chromium-enriched passive layer. In addition to naturally occurring passivation, chemicals such as nitric acid, phosphoric acid, citric acid, and formulated phosphoric acid–citric acid blends can passivate stainless steel (2–4).
The quality of the passive layer can be assessed through various methods, including X-ray photoelectron spectroscopy (XPS). XPS commonly helps scientists validate chemical treatments. Before passivation, operators rinse mechanically polished stainless-steel panels with isopropyl alcohol, high-purity water, acetone, and again with high purity water. After passivation treatment, operators remove the panels, rinse them with high-purity water, and allow them to air dry. Figure 1 shows the results of an XPS analysis (5, 6). The chromium–iron ratio at the surface of the untreated sample is approximately 0.25 Å, while that of the samples treated with formulated or commodity citric acid is approximately 2.0 Å.
Types and causes of rouge
Rouge occurs in most biopharmaceutical facilities and often is associated purified-water systems, clean-steam systems, buffer-preparation tanks (especially sodium-chloride or glycine-solution preparations), filling lines, vial washers (which typically are cleaned with hot purified water), and steam sterilizers. Rouge results from exposure to highly aggressive environments such as purified-water or -steam systems, chloride or corrosive products, and high-temperature stress or erosion. Other factors that cause rouge are nonstainless-steel components or inserts, improper welding, surface defects, and inadequate cleaning or passivation.
Consistent procedures reduce downtime
Qualified engineering or maintenance staff should inspect in-use equipment for rouge. Surface inspection will help determine whether the equipment needs to be derouged and passivated. If no program is in place, a semiannual inspection is recommended as a starting point.
Laboratory evaluation can help determine the best conditions (e.g., chemistry, concentration, time, and temperature) for removing specific types of rouge. A facility’s routine acid cleaner, when used at a higher concentration and for a longer time, may effectively remove the rouge and restore the passive layer.
Low-level preventive derouging and passivation
The author generated laboratory rouge by suspending a preweighed 304 stainless-steel coupon and mild steel coupon in a 1% sodium-chloride solution while mixing for one week. The laboratory-generated rouged coupons were then treated with water, citric acid, formulated citric acid, or phosphoric-acid detergent at 60 °C for 30 min. The results, shown in Figure 3, indicate that low-level concentration and temperature conditions can remove rouge.
A low-concentration acid rinse after an alkaline wash step has potential benefits for regular preventive maintenance, derouging, and passivation. Compared with removing the equipment from the production line completely to deal with rouge buildup, a low-level clean-in-place approach can save time, cost, and labor in the long run. In addition, preventive-maintenance programs that include routine inspection of equipment surfaces and piping, and specific derouging and passivation procedures, can reduce costly equipment downtime significantly.
Paul Lopolito is a technical services specialist at STERIS, Mentor, OH, firstname.lastname@example.org.